Literature DB >> 25656088

Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.

Sai-Sai Xie1, Jin-Shuai Lan1, Xiao-Bing Wang1, Neng Jiang1, Ge Dong1, Zhong-Rui Li1, Kelvin D G Wang1, Ping-Ping Guo1, Ling-Yi Kong2.   

Abstract

Combining tacrine with trolox in a single molecule, novel multifunctional hybrids have been designed and synthesized. All these hybrids showed ChE inhibitory activity in nanomolar range and strong antioxidant activity close to the parent compound trolox. Among them, compound 6d was the most potent inhibitor against AChE (IC50 value of 9.8 nM for eeAChE and 23.5 nM for hAChE), and it was also a strong inhibitor to BuChE (IC50 value of 22.2 nM for eqBuChE and 20.5 nM for hBuChE). Molecular modeling and kinetic studies suggested that 6d was a mixed-type inhibitor, binding simultaneously to CAS and PAS of AChE. In vivo hepatotoxicity assays indicated that 6d was much less toxic than tacrine. In addition, it showed neuroprotective effect and good ability to penetrate the BBB. Overall, all these results highlighted 6d a promising multifunctional agent for AD treatment.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Antioxidant; Cholinesterase; Hepatotoxicity; Tacrine; Trolox

Mesh:

Substances:

Year:  2015        PMID: 25656088     DOI: 10.1016/j.ejmech.2015.01.058

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

Review 1.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

Review 2.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

Review 3.  Medicinal chemistry of acridine and its analogues.

Authors:  Parteek Prasher; Mousmee Sharma
Journal:  Medchemcomm       Date:  2018-08-14       Impact factor: 3.597

Review 4.  Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.

Authors:  Wen-Yu Wu; Yu-Chen Dai; Nian-Guang Li; Ze-Xi Dong; Ting Gu; Zhi-Hao Shi; Xin Xue; Yu-Ping Tang; Jin-Ao Duan
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

5.  Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease.

Authors:  Jin-Shuai Lan; Jian-Wei Hou; Yun Liu; Yue Ding; Yong Zhang; Ling Li; Tong Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 6.  Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential.

Authors:  Saikat Mitra; Maniza Muni; Nusrat Jahan Shawon; Rajib Das; Talha Bin Emran; Rohit Sharma; Deepak Chandran; Fahadul Islam; Md Jamal Hossain; Sher Zaman Safi; Sherouk Hussein Sweilam
Journal:  Oxid Med Cell Longev       Date:  2022-08-18       Impact factor: 7.310

7.  Synthesis, structure, antioxidant activity, and water solubility of trolox ion conjugates.

Authors:  Yuliya V Yushkova; Elena I Chernyak; Yuriy V Gatilov; Vladimir G Vasil'ev; Sergey V Morozov; Igor A Grigor'ev
Journal:  Saudi Pharm J       Date:  2017-10-10       Impact factor: 4.330

8.  Conjugates of Tacrine with Salicylamide as Promising Multitarget Agents for Alzheimer's Disease.

Authors:  Maria V Grishchenko; Galina F Makhaeva; Yanina V Burgart; Elena V Rudakova; Natalia P Boltneva; Nadezhda V Kovaleva; Olga G Serebryakova; Sofya V Lushchekina; Tatiana Y Astakhova; Ekaterina F Zhilina; Evgeny V Shchegolkov; Rudy J Richardson; Victor I Saloutin
Journal:  ChemMedChem       Date:  2022-03-23       Impact factor: 3.540

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.